History

Scientific discoveries and milestones.

1992

The Swedish mutation, which leads to early development of Alzheimer’s disease, was discovered in a Swedish family by Professor Lars Lannfelt

2000

US patent application filed on the discovery of the Arctic mutation, and its propensity to form amyloid-beta oligomers/protofibrils a target for drug intervention

2001

The discovery of the Arctic mutation was published. The Arctic mutation leads to increased production of amyloid-beta oligomers/protofibrils and early development of Alzheimer’s disease. This gave an insight into a new target for treatment of Alzheimer’s disease: amyloid-beta oligomers/protofibrils

2003

BioArctic Neuroscience AB was founded by Lars Lannfelt and Pär Gellerfors

2004

Karolinska Innovation AB invested in BioArctic (the asset was later transferred to Karolinska Development AB)

Concerning a transgenic mouse model (APPArcSwe), BioArctic filed two important patent applications concerning a transgenic mouse model and a concept patent for antibody treatment of Alzheimer’s disease

2005

The drug candidate mAb158 (precursor to BAN2401) was isolated at Uppsala University, in Sweden

BioArctic and Eisai entered into a research collaboration concerning a disease modifying treatment for Alzheimer’s disease

BioArctic started research on Parkinson’s disease in collaboration with Uppsala University

Uppsala University Holding AB invested in BioArctic

2006

BioArctic was located in own premises in Stockholm, in Sweden

2007

BioArctic and Eisai entered into a license agreement concerning the antibody BAN2401 as a disease modifying treatment of Alzheimer’s disease as a result of the research collaboration agreement of 2005

The second US patent for Alzheimer’s disease was granted

BioArctic filed a patent application concerning the antibody BAN2401

2008

BioArctic and Eisai entered into a second research collaboration concerning a back-up antibody to BAN2401

2012

BioArctic signed an extension of the ongoing research collaboration with Eisai on immunotherapy for Alzheimer’s disease

2013

BioArctic’s partner Eisai started a clinical Phase 2b study in the US concerning the drug candidate BAN2401 and the clinical development of BAN2401 was started in Japan

2014

The clinical development of BAN2401 in Alzheimer’s disease was started in Europe

BioArctic’s partner Eisai entered into an agreement with Biogen concerning the continued development and commercialization of BAN2401 in Alzheimer’s disease

2015

BioArctic and Eisai entered into a license agreement concerning BAN2401 Back-up, a follow-up project to BAN2401, and a third research collaboration agreement concerning a new disease modifying treatment for Alzheimer’s disease

BioArctic’s research program on Parkinson’s disease received grants from Swedish Vinnova and the EU’s research and development program Horizon2020 (Grant Agreement No. 697790)

2016

The company’s name was changed from BioArctic Neuroscience AB to BioArctic AB

BioArctic entered into a collaboration agreement with AbbVie concerning research on Parkinson’s disease

2017

The patent for BAN2401 backup was granted in the US

BioArctic received two grants from Swedish Vinnova for the company’s work with the quality management system and the commercial potential of antibody-based PET imaging

Trading in BioArctic’s B-shares commenced October 12th on Nasdaq Stockholm

BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, was granted in Europe

2018

Positive BAN2401 Phase 2b clinical study results in early Alzheimer’s disease

Exclusive rights to develop the antibody AD1801 (in discovery) for Alzheimer’s disease

Expanded research collaboration with Uppsala University, Sweden, concerning antibody-based diagnostic imaging of the brain in Alzheimer patients

Research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease

Out-licensing of the portfolio of antibodies targeting alpha-synuclein to AbbVie for Parkinson’s disease and other potential indications

Granted concept patent in Europe for treatment strategy for disease-modifying treatment of Parkinson’s disease

Grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s disease

Extended research collaboration with Uppsala University regarding new antibody technologies for increased passage across the blood-brain barrier (BBB-technology)